<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01512446</url>
  </required_header>
  <id_info>
    <org_study_id>2011.1.42</org_study_id>
    <secondary_id>2011-000290-31</secondary_id>
    <nct_id>NCT01512446</nct_id>
  </id_info>
  <brief_title>Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy</brief_title>
  <acronym>BILANZ</acronym>
  <official_title>Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Evangelisches Krankenhaus Lutherhaus gGmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Evangelisches Krankenhaus Lutherhaus gGmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of bisphosphonates in long
      term treatment of osteoporosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Is a continued treatment with alendronate for another two years after a preceding therapy
      with bisphosphonates of at least four years able to reduce the incidence of new osteoporotic
      fractures in patients at high fracture risk compared to a therapy-free interval?
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low recruitment rate
  </why_stopped>
  <start_date type="Actual">February 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of new osteoporotic fractures</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Equivalence of deaths with and without continued bisphosphonate therapy</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of the combination of fractures and deaths</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">436</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Alendronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate</intervention_name>
    <description>70 mg per week</description>
    <arm_group_label>Alendronate</arm_group_label>
    <other_name>Fosamax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 pill per week</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women or men &gt; 60 years

          -  DXA T-Score at lumbar spine, total hip or femur neck &lt;-2,0 before the start of the
             bisphosphonate therapy or at baseline or at least one low trauma vertebral fracture
             grade 2-3 or multiple low trauma vertebral fractures independent of bone mineral
             densitiy

          -  Pretreatment with bisphosphonates for at least four years

          -  Risk for hip and vertebral fractures min. 30% according to DVO-guideline for
             osteoporosis 2009

          -  Signed informed consent

        Exclusion Criteria:

          -  Other pharmacological treatment of osteoporosis during the last 48 months

          -  Other bone diseases

          -  Malabsorption syndromes

          -  Renal insufficiency with a calculated creatinine clearance &lt; 35 ml/min

          -  Diseases of the esophagus, delayed esophageal clearance

          -  UUnability to realise the intake instructions

          -  Hypocalcemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Pfeilschifter, Prof. Dr. med.</last_name>
    <role>Study Director</role>
    <affiliation>Alfried Krupp Krankenhaus Essen Steele</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Internal Medicine III, Alfried Krupp Krankenhaus Essen Steele</name>
      <address>
        <city>Essen</city>
        <zip>45276</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2012</study_first_submitted>
  <study_first_submitted_qc>January 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2012</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <keyword>Osteoporotic fractures</keyword>
  <keyword>Bisphosphonate</keyword>
  <keyword>Pretreatment with bisphosphonates</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 28, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

